Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P10301
UPID:
RRAS_HUMAN
Alternative names:
p23
Alternative UPACC:
P10301; Q6FH12
Background:
Ras-related protein R-Ras, also known as p23, plays a crucial role in regulating the organization of the actin cytoskeleton, as evidenced by studies (PubMed:16537651, PubMed:18270267). It also collaborates with OSPBL3 to modulate the activity of integrin beta-1 (ITGB1), highlighting its significance in cellular adhesion and signaling (PubMed:18270267).
Therapeutic significance:
Understanding the role of Ras-related protein R-Ras could open doors to potential therapeutic strategies, especially in disorders where actin cytoskeleton organization and integrin activity are compromised.